IOM will be called the National Academy of Medicine effective July 1, 2015.
The National Academy of Sciences has voted to change the name of the Institute of Medicine to the National Academy of Medicine effective July 1 as part of broader internal reorganization.
The newly named entity will continue to be an honorific society and inherit more than 1,900 current elected members and foreign associates of the IOM. It joins the National Academy of Sciences and National Academy of Engineering in advising the nation on matters of science, technology, and health. Officials said the change was part of efforts to more effectively integrate the work of the National Academies of Sciences, Engineering, and Medicine.
Reports and studies on health and medicine will continue to appear as activities of the Institute of Medicine, which will become one of the six program units operating under the direction of the integrated academies.
Reported by The Commonwealth Fund: http://bit.ly/1ELwdz0
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Poor Well-Being Scores Linked to Early Treatment Stoppage in Multiple Myeloma
March 27th 2024Investigators used the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale to collect data on patient-reported treatment-related adverse effects, to provide clinicians guidance on predicting risk of early treatment discontinuation among ECOG-ACRIN E1A11 trial participants.
Read More